ARES

SmartHealth Technological development Trajectories: 
Innovative Therapy
Tipologia progetto: 
Strategico

Against bRain cancEr: finding personalized therapies with in Silico and in vitro strategies

This project presents an innovative approach towards a personalized treatment and therapy of glioblastoma (GBM), the most common malignant primitive brain tumor. With currently available therapies (surgery followed by chemo and radio therapy) the average life expectancy of the affected patients is only one year. Surgery alone is not able to completely eradicate the tumor due to the infiltrative nature of GBM. Additionally, the cancer cells can rapidly develop resistance to currently available therapies. Through the union of the scientific and technological skills of the partners, innovative experimental and computational techniques will be developed and integrate, in order to identify an effective system to face the disease.

Starting from the study of Glioblastoma cells (GSC) and with the support of an advanced integrated technology platform, innovative methods of analysis, evaluation and treatment will be implemented and subsequently compared with the currently systems used in the therapeutic field.

 

At the end of the project a glioblastoma stem cell bank will be available for implementation; new 3D in vitro models (to study the invasiveness of GBM cells) will be created; the results of the effectiveness evaluation tests of the molecules identified as candidates capable of blocking GBM growth will be formalized.

Furthermore, the following outputs will be developed with the possibility of future commercial use:

  • an integrated technological platform (Ecosystem) to be used in the area of advanced health data services;
  • diagnostic kits for in vitro prediction of the therapy response

 

The project aims are:

  1. the identification of new therapies capable of blocking the proliferative and infectious capacity of GBM tumor cells, possibly extending these therapies to low-grade gliomas, to find an effective cure even in the initial phase of the disease;
  2. the development of new assays able to predict patients' response to drugs, thus allowing a personalization of the therapy.
Documentazione: 
PDF icon Poster ARES
September 2018 to March 2021
Costo totale: 
€1.085.820,00
Contributo finanziato
€ 833.433,00
Project leader
eXact-lab Srl
Partners
CNR-IOM - Istituto Officina dei Materiali
Attività di CBM
dissemination
poster ares
  • ministero dell'istruzione dell'universita e della ricerca
  • regione fvg
  • Area Science Park
  • ProESOF 2020